XXX reprioritization our cancers and product everyone. product to and significant cell pipeline months. We unmet a and are and focus XX XX Rich, towards to on candidates on for clinical acting robust dual advancing RORX medical announced with XXX targeting AR within preclinical afternoon, catalysts next advancing inhibitor strategic the good a need. our novel we clinical Oncternal, therapy on patients recently you, Thank that target At with focused
ibrutinib X, we by the mantle our tyrosine decided Phase shifts of April X/X of ibrutinib’s and time, decision an unmet hematologic studies same the to expected partner followed cancer. our X kinase Phase which XXXX important by with our to malignancies announcement and both This approval with us allowed in cash to on was At due in close major withdraw to mission our lymphoma. combination to extend prostate landscape, runway FDA patients cell in accelerated inhibitor needs their into Bruton's Zilovertamab plans and reinforces for address
clinical by of on-target is targeting antibody, is driven of the was our autologous leverages be Looking found experience targeted safe be in a to X the several potential very data clinical off-tumor, RORX studies. trial. targeting which being tumor to Zilovertamab activity. Zilovertamab, with can and Specificity our clinical extensive is for CAR drug Phase about T RORX X on which antibody using shown recently future, without from conjugate, XXX excited XXX, On in also clinical we and are initiated testing unwanted X/X which cells Phase the investigated same that
tumor and from robust ONCT-XXX specific show cytotoxic models of RORX expressing cells preclinical types. Our multiple activity against
Our and manufacturing in scalable, process is only X reproducible, days duration.
initial with readouts guided, additional clinical XXXX readout XXXX. in late previously data expect clinical we As in our data
dose will Using therapy. enroll T that X investigate doses. a of to CAR have failed X-Stage exert will help at the Phase ONCT-XXX-XXX X three will aggressive doses this can CD-XX ONCT-XXX X increasing Phase dose. who Our escalation dose of of three B-cell and previous refractory help to design, and determine dose similar evaluate using study the relapse further In lymphoma, those safety anti-tumor effects expressing recommended be Phase be ONCT-XXX. efficacy other design. the CAR [indiscernible] X/X Xx standard Phase T-cells effective dose plus us evaluated which T including will Simon The patients T-cells products with study potential considering Phase kilogram X, be the us to per to starting will recommended has CAR
reminder, CDXX months. little treatment responding need survival patients and have treatment failed the with a survival have extreme As medical overall of median who months X to of only unmet progression-free only of next likelihood X and
novel We both are ONCT-XXX, also inhibits very androgen receptor AR first its action inhibitor, activity in-class induces which enthusiastic degradation. and about our and dual
enabling Ligand IND and the for it IND the concluded are now both of assembling have AR. the directed are in to and submitting on we suggest binding Preclinical activity studies domains track We mid-XXXX. N-terminal and models
even is LBD. clinical active cleared. AR resistant models are to is lacking care prostate IND after -- Phase forms against AR active AR though is in current and castration constituently trial with to expected AR directed metastatic standard X/X shortly that mutations to LBD including open resistance of preclinical therapies the variants of common who cancer the ONCT-XXX of amplification, patients most resistant splice are treatment the standard inhibitor
results expect to clinical initial We present mid-XXXX. in
CFO, Let me call the to Vincent. back now Rich turn Oncternal
